NCT07095465View on ClinicalTrials.gov

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

March 31, 2029

Conditions
Lewy Body Dementia Psychosis
Interventions
DRUG

ACP-204

Provided as 1 capsule, to be taken orally once daily

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY